Qiagen (QGEN) said Tuesday the German Federal Patent Court reaffirmed the validity of a patent protecting its QuantiFeron technology.
The court's decision upholds Qiagen's intellectual property rights involving the German part of a European patent, which protects its technology in detecting latent tuberculosis, the company said late Tuesday.
"Patents covering these innovations have been issued to Qiagen in several other countries, and form part of a group of more than 120 patents currently issued for QuantiFERON," the company added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.